You are here:
Arsenic: Carcinogenic Mechanisms, Risk Assessment and the Maximum Contaminant Level (MCL)
Citation:
Kitchin, K T. AND B. D. Beck. Arsenic: Carcinogenic Mechanisms, Risk Assessment and the Maximum Contaminant Level (MCL). Presented at Society of Toxicology, Philadelphia, PA, March 19-23, 2000.
Description:
This workshop will provide an up-to-date overview on key issues related to cancer risk assessment of arsenic: carcinogenic mechanisms; application of mechanistic information to risk assessment models; and the development of the MCL for arsenic in drinking water. The two presentations on mechanisms will focus on the possible role of methylated arsenic species as mediators of carcinogenesis. Dr .Kitchin will briefly summarize proposed carcinogenic mechanisms for arsenic and will address the possible , role of methylated arsenic metabolites. in particular dimethylarsinic acid (DMA), in carcinogenesis. Dr. Fukushima will present current
(and controversial) studies of DMA as a rodent multi-organ tumor promoter and a rat urinary bladder complete carcinogen. The next two presentations will describe risk assessment models for use in quantifying exposures and risks of arsenic. Dr. Mann will describe a physiologically based pharmacokinetic (PBPK) model for inhaled and oral exposures to arsenic, evaluating the validity of this model under different exposure conditions. A biologically-based dose- response model for arsenic based on understanding of arsenic's mode- of-action will be described by Clewell. Finally, Dr. Abemathy will address the important issue of setting an MCL for arsenic. describing not only the toxicologic and risk issues. but also issues of feasibility and implementation. It is expected that this workshop will be of interest to a broad range of scientists, including basic researchers, risk assessors, and regulators
This is an abstract of a proposed presentation and does not necessarily reflect EPA policy.